AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02438046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal wound bandage
Description: Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
Study NCT02438046 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Palatal wound bandage
Description: Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
Study NCT01412151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Creatine monohydrate
Description: Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
Study NCT05351463 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: papila suture technique
Description: simple interupted vs internal horoizontal matress suture
Study NCT02499575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
Study NCT02499575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
Study NCT02499575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
Study NCT00573781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet with increased intake of rye bread, berries and fish
Description: Dietary modification with commercial food items
Study NCT00573781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Increased intake of whole grain and rye bread
Description: Dietary modification with commercial food items
Study NCT00573781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control diet with decreased intake of rye bread, berries and fish
Description: Dietary modification with commercial food items
Study NCT01256320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Egg Group
Description: consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
Study NCT01256320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 Egg Group
Description: consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
Study NCT02417610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polynucleotide - PNHA - Newart
Description: gel polynucleotides and hyaluronic acid
Study NCT02417610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - HA - Ialart
Description: Hyaluronic acid
Study NCT02890745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT02890745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00910910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
Study NCT00910910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
Study NCT05648877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscope
Description: Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
Study NCT05648877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteroscope
Description: Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
Study NCT00853710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA assay
Description: rapid prostate specific antigen assay.
Study NCT03075306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention
Description: the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
Study NCT02869581 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT02382783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FLARE Intervention Group
Description: Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported.
Study NCT03194308 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PrEP for Safer Conception
Description: Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
Study NCT00678171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLIF with a PEEK Spacer System and XIA Spinal System
Description: TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
Study NCT00678171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLIF with a PEEK Spacer System and XIA Spinal System
Description: TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
Study NCT02835612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early stimulation
Description: Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
Study NCT02835612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
Study NCT00127491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an esophageal balloon measurements
Description: In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
Study NCT00127491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of an esophageal balloon measurements
Description: In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
Study NCT00127491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low tidal volume ventilation
Description: Low tidal volume ventilation strategy (ARDSnet)
Study NCT00127491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure-directed ventilation (EPVent)
Description: Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
Study NCT04501601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable solid drink
Description: weight loss program supplement
Study NCT02010593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
Study NCT02010593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Ring
Description: The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
Study NCT04311970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EsoCheck
Description: All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
Study NCT01135459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-33457
Description: CEP-33457 will be administered per dose and schedule specified in the arm description.
Study NCT01135459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
Study NCT04073511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eungyosan
Description: This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
Study NCT04073511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samsoeum
Description: This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
Study NCT04073511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2 ml 0.9% saline (placebo)
Study NCT04633395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The participant can choose between 5 different soothing playlists
Study NCT04633395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: These are behavioural guidelines to help establish a better sleep pattern
Study NCT04633395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: These are behavioural guidelines to help establish a better sleep pattern
Study NCT01822899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide/Vilanterol
Description: Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
Study NCT01822899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ACCUHALER/DISKUS
Description: Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
Study NCT01822899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/Salmeterol
Description: Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
Study NCT01822899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo NDPI
Description: Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
Study NCT05401344 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: test strips,sponges and cold dry air test
Description: Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
Study NCT02466477 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GeneSight Psychotropic (GEN)
Description: Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Study NCT02466477 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Enhanced-GeneSight Psychotropic (E-GEN)
Description: The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 8 mg (2 ml)
Study NCT02466477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
Study NCT02628405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02628405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02628405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT02628405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02628405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02628405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01821092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion and abutment connection
Description: After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
Study NCT01821092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: osseointegrated implant
Description: Osseointegrated Implant Insertion
Study NCT01458743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: 60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
Study NCT01458743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
Study NCT01692496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
Study NCT00306839 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standardized Lichtenstein technique
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine
Description: 30 ml 0.5% ropivacaine
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: 30 ml 0.5% ropivacaine
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5% bupivacaine
Study NCT00801138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5% bupivacaine
Study NCT03083275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Study NCT03410134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoMTA
Description: NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
Study NCT00094835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
Study NCT00094835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motesanib diphosphate
Description: Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
Study NCT01354990 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin (JANUVIA®)
Description: Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
Study NCT03821649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOONER Training and Naloxone Kit Kit
Description: Participants are shown our unique overdose response education video and given the associated kit to take home.
Study NCT03821649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community or Hospital-Based Training
Description: Referral to standard of care for Naloxone training
Study NCT01976338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: intravitreal injection of 0.05 ml
Study NCT01976338 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham intravitreal injection
Study NCT00807586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 100mg, given once within 2 hours of the end of the ablation procedure
Study NCT00807586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (1.6 cc)
Study NCT03130517 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immunoglobulin
Description: giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
Study NCT02357537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Anti-inflammatory Diet (CAID)
Description: The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
Study NCT04792788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from mechanical ventilation
Description: Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
Study NCT00725946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-124
Study NCT00725946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT with Iodine-124
Study NCT01794507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
Study NCT01794507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
Study NCT01794507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
Study NCT03885154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
Study NCT03885154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine (DHE)
Description: 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg